Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (11-20 of 616) with videos related to

Pageof 62
Sort By:
Clinical and Molecular Hepatology|September 18, 2023
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trialsMing-Lun Yeh, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 10, 2025
Response to the Letter to the Editor Regarding "Assessing the link between post-treatment ALT and HCC risk in chronic hepatitis C"Yen-Chun Chen, Ming-Lung Yu
Journal of Hepatology|April 25, 2020
Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey"Ming-Lun Yeh, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 22, 2025
Reply to the comment on "High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C"Yen-Chun Chen, Ming-Lung Yu
Journal of Gastroenterology|October 30, 2012
Host factors determining the efficacy of hepatitis C treatmentWan-Long Chuang, Ming-Lung Yu
Clinical and Molecular Hepatology|April 11, 2024
Reply to correspondence on "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide"Pin-Nan Cheng, Ming-Lung Yu
The Kaohsiung Journal of Medical Sciences|December 18, 2020
Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020Ming-Lung Yu, Wan-Long Chuang
Hepatitis Research and Treatment|December 15, 2010
Evolution of interferon-based therapy for chronic hepatitis CChun-Hao Chen, Ming-Lung Yu
Expert Opinion on Pharmacotherapy|November 1, 2017
Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developmentsChung-Feng Huang, Ming-Lung Yu
Kidney International|February 24, 2020
Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infectionChung-Feng Huang, Ming-Lung Yu
Pageof 62

Showing results (11-20 of 616) with videos related to

Sort By:
Pageof 62
Clinical and Molecular Hepatology|September 18, 2023
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trialsMing-Lun Yeh, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 10, 2025
Response to the Letter to the Editor Regarding "Assessing the link between post-treatment ALT and HCC risk in chronic hepatitis C"Yen-Chun Chen, Ming-Lung Yu
Journal of Hepatology|April 25, 2020
Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey"Ming-Lun Yeh, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 22, 2025
Reply to the comment on "High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C"Yen-Chun Chen, Ming-Lung Yu
Journal of Gastroenterology|October 30, 2012
Host factors determining the efficacy of hepatitis C treatmentWan-Long Chuang, Ming-Lung Yu
Clinical and Molecular Hepatology|April 11, 2024
Reply to correspondence on "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide"Pin-Nan Cheng, Ming-Lung Yu
The Kaohsiung Journal of Medical Sciences|December 18, 2020
Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020Ming-Lung Yu, Wan-Long Chuang
Hepatitis Research and Treatment|December 15, 2010
Evolution of interferon-based therapy for chronic hepatitis CChun-Hao Chen, Ming-Lung Yu
Expert Opinion on Pharmacotherapy|November 1, 2017
Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developmentsChung-Feng Huang, Ming-Lung Yu
Kidney International|February 24, 2020
Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infectionChung-Feng Huang, Ming-Lung Yu
Pageof 62